What Is the Controlled Substances Act and How Does It Affect Psychedelics?

Last reviewed: August 2026 · Psychedelic law changes quickly — verify current status before relying on this page.

Who this is for: Anyone who wants to understand the federal law that governs psychedelics in the United States — including founders, researchers, clinicians, and professionals who need to understand the system before making decisions that touch it.

The short answer

The Controlled Substances Act is the federal law that classifies and regulates drugs in the United States. Enacted in 1970, it is the reason most psychedelics are federally illegal regardless of what any state or city has done. Most psychedelics were placed in Schedule I when the CSA was enacted and have remained there since.

Why people get confused

Most people encounter the word “scheduling” without understanding what it means structurally. They know psilocybin is “Schedule I” and that this is bad. They do not know what Schedule I actually requires, who made that determination, or what it would take to change it. Without that, it is easy to misread developments in the space — assuming that a Breakthrough Therapy designation means a substance is nearly legal, or that state programs modify federal classification. They do not.

What the Controlled Substances Act is

The Controlled Substances Act is Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, signed into law by President Richard Nixon on October 27, 1970 and codified at Title 21 of the United States Code.

The CSA consolidated existing federal drug laws into a single statute and established a national system for regulating the manufacture, distribution, importation, exportation, and dispensing of controlled substances. It also fulfilled US obligations under two international treaties: the Single Convention on Narcotic Drugs of 1961, and the Convention on Psychotropic Substances, which entered into force in 1976.

The Drug Enforcement Administration — established in 1973 by combining the Bureau of Narcotics and Dangerous Drugs with customs drug agents — is the federal agency primarily responsible for implementing and enforcing the CSA.

How the scheduling system works

The CSA divides all regulated substances into five categories, called schedules, based on three criteria: the substance’s potential for abuse, its currently accepted medical use in the United States, and its safety or dependence liability. A lower schedule number corresponds to greater restrictions.

Schedule I is the most restrictive. To be placed in Schedule I, a substance must meet three criteria simultaneously: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use even under medical supervision. Schedule I substances cannot be legally prescribed, administered, or dispensed. No practitioner has authority to prescribe them regardless of state law.

Schedule II substances also have a high potential for abuse but have a currently accepted medical use — with or without severe restrictions. That distinction is what separates fentanyl, oxycodone, and methamphetamine (Schedule II) from heroin and psilocybin (Schedule I).

Schedules III through V reflect progressively lower abuse potential and correspondingly relaxed controls. Ketamine is Schedule III — which is why licensed physicians can prescribe it. It has a currently accepted medical use and sits in a schedule that permits prescription.

Psilocybin, LSD, MDMA, DMT, mescaline, ibogaine, and most classical psychedelics are Schedule I. Cannabis also remains Schedule I federally, though the DEA published a proposed rule in 2024 to move it to Schedule III. That rulemaking has not been finalized.

What Schedule I means in practice

Schedule I classification has three direct consequences.

No prescriptions are possible. No physician, psychiatrist, or other licensed prescriber has the authority to write a prescription for a Schedule I substance. This is true regardless of what any state program permits. Oregon’s psilocybin program does not involve prescriptions — it operates as a supervised access model under state law, separate from the federal prescription pathway.

Handling legally requires DEA registration. Researchers who want to study Schedule I substances must obtain a Schedule I researcher registration from the DEA — a process separate from, and in addition to, any FDA authorization for a clinical trial. This registration comes with strict requirements for storage, security, record-keeping, administration, and disposal. Moving study drug between registered locations can require a police escort.

Possession, manufacture, and distribution without authorization are federal crimes. Without a DEA registration or other specific exemption, any possession, manufacture, or distribution of a Schedule I substance is a federal crime. The fact that an activity occurs within a state-licensed program does not provide a federal defense.

Who decides what gets scheduled — and how it can change

The scheduling process involves three actors: the DEA, the Department of Health and Human Services acting through the FDA, and Congress.

The DEA is the primary agency responsible for scheduling decisions. It can initiate proceedings on its own or in response to a petition from any interested party — including drug manufacturers, medical associations, state agencies, or private citizens.

Before the DEA can act, it must request a scientific and medical analysis from HHS. The FDA prepares this analysis under an eight-factor framework set out in 21 U.S.C. § 811(c), which covers the substance’s actual potential for abuse, scientific knowledge of its pharmacological effects, its history and current pattern of abuse, risk to public health, and its psychological or physiological dependence liability. HHS’s scientific and medical findings are binding on the DEA — if HHS concludes a substance lacks currently accepted medical use, the DEA must keep it in Schedule I.

Congress retains ultimate authority and can reschedule or deschedule any substance by passing legislation. This path bypasses the DEA-FDA administrative process entirely and is not subject to the Administrative Procedure Act. Congress has used this authority before — placing GHB in Schedule I and anabolic steroids in Schedule III through standalone legislation.

There are three recognized pathways to change a substance’s schedule: legislation by Congress, administrative rulemaking initiated by the DEA following a petition, and rescheduling that follows FDA approval of a drug product containing the substance. If psilocybin or MDMA ever received full FDA approval, that approval would trigger a mandatory scheduling review.

Where psilocybin rescheduling currently stands

Psilocybin remains Schedule I. Psilocybin has received Breakthrough Therapy designation from the FDA for treatment-resistant depression and major depressive disorder — a research designation that accelerates clinical review timelines but does not change scheduling or create any legal access.

In August 2025, the DEA transmitted a psilocybin rescheduling petition to HHS, forwarding a petition originally filed by Dr. Sunil Aggarwal and the Advanced Integrated Medical Science Institute. HHS, acting through the FDA, must now conduct a scientific and medical evaluation and issue a scheduling recommendation. If HHS recommends rescheduling, that recommendation is scientifically binding on the DEA, which must then initiate formal rulemaking. No final determination has been made.

How Schedule I classification affects different people

For individuals, possession of most psychedelics is a federal crime regardless of state law. Participating in a licensed Oregon or Colorado psilocybin session involves handling a federally prohibited substance in a state-regulated setting. Federal enforcement against individual session participants has been rare, but that reflects prosecutorial discretion.

For researchers, Schedule I classification creates a substantial compliance burden. A DEA Schedule I researcher registration is required, separate from any FDA authorization. The registration requires institutional support, approved storage and security, and strict protocols for handling, administration, and disposal. The process is time-consuming and approval is not guaranteed.

For businesses, Schedule I classification creates problems that state licensing does not solve: banking, federal tax treatment, federal contracting, and securities law all interact with the federal prohibition in ways no state program can override.

For licensed professionals, a physician cannot prescribe psilocybin even in a state with a regulated program. The facilitator role exists precisely because the supervised-access model in Oregon and Colorado was built around the absence of a prescription pathway.

Common mistakes and misconceptions

“Breakthrough Therapy designation means it’s almost legal.” Breakthrough Therapy is a research designation that allows the FDA to work more closely with a sponsor to accelerate clinical development. It does not change scheduling or signal imminent approval.

“State programs changed the federal law.” Oregon and Colorado created state-level regulatory frameworks. They cannot modify the CSA. A substance can be regulated for supervised access under state law and remain Schedule I federally at the same time.

“If the DEA approved a research registration, it must be okay.” DEA research registrations permit specific researchers to handle a Schedule I substance under tightly controlled conditions for a specific protocol. They are not signals that a substance’s scheduling is under review.

“Rescheduling from I to II would make it widely available.” Rescheduling to Schedule II would permit prescription by licensed practitioners and allow commercial manufacture and distribution under DEA controls. It would not mean open access. Schedule II includes fentanyl, oxycodone, and methamphetamine — all tightly controlled substances.

When public information may be enough

If you are trying to understand what the CSA is, how scheduling works, and why most psychedelics remain federally illegal, this article covers that. For substance-specific detail, see Psilocybin, MDMA, ketamine, and cannabis: why the law treats them differently.

When you should speak with a lawyer

You should speak with a lawyer when the CSA’s structure is an active factor in a decision you are making. That includes:

You are a researcher trying to understand the DEA registration process and what it requires
You are a founder building a business around a Schedule I substance and want to understand your actual federal risk exposure
You are a licensed professional who has received or is considering a DEA registration and want to understand what it permits and what it does not
You are operating in a state-licensed program and want to understand how federal law interacts with your specific activities
You have received any communication from the DEA or any federal agency related to controlled substance handling

You might also want to read

This article is public legal education, not legal advice. If your situation is specific, speak with a lawyer who practices in this area.